DiaMedica Therapeutics SG&A Expenses 2015-2024 | DMAC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

DiaMedica Therapeutics sg&a expenses from 2015 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

DiaMedica Therapeutics sg&a expenses from 2015 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.5B
Vertex Pharmaceuticals (VRTX)	$121.6B
Gilead Sciences (GILD)	$111.4B
Bristol Myers Squibb (BMY)	$110.2B
Regeneron Pharmaceuticals (REGN)	$93B
CSL (CSLLY)	$90B
GSK (GSK)	$76.4B
Argenex SE (ARGX)	$35.6B
Alnylam Pharmaceuticals (ALNY)	$35.3B
BioNTech SE (BNTX)	$26.5B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$23.9B
Moderna (MRNA)	$21B
BeiGene (BGNE)	$19.9B
Genmab (GMAB)	$14.9B
Incyte (INCY)	$14.7B
Exact Sciences (EXAS)	$12.9B
BioMarin Pharmaceutical (BMRN)	$12.7B
Vaxcyte (PCVX)	$12B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.8B
Insmed (INSM)	$11.7B
QIAGEN (QGEN)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.3B
Revolution Medicines (RVMD)	$9.2B
Intra-Cellular Therapies (ITCI)	$9.2B
Roivant Sciences (ROIV)	$8.6B
Viking Therapeutics (VKTX)	$8.1B
Legend Biotech (LEGN)	$8.1B